TRANSMITTED HIV-1 DRUG RESISTANCE IN THE START STUDY USING NEXT GENERATION SEQUENCING

Objectives: The aim of this analysis was to characterize transmitted drug resistance (TDR) in START study participants by next generation sequencing (NGS), a sensitive assay capable of detecting low-frequency variants. Methods: Stored plasma from participants with entry HIV RNA >1,000 copies/ml were analyzed by NGS (Illumina MiSeq). TDR was based on the WHO 2009 surveillance definition with the addition of reverse transcriptase (RT) mutations T215N and E138K, and integrase strand transfer inhibitor (INSTI) surveillance mutations (Stanford HIVdb). Drug resistance mutations (DRMs) detected at three thresholds are reported: above 2%, 5%, and 20% of the viral population. Results: Between 2009-2013, START enrolled 4,684 ART-naïve individuals in 35 countries. Baseline NGS data at study entry was available for 2,902 participants. Overall prevalence of TDR using a detection threshold of 2%/5%/20% was 9.2%/5.6%/3.2% for NRTIs, 9.2%/6.6%/4.9% for NNRTIs, 11.4%/5.5%/2.4% for PIs, and 3.5%/1.6%/0.1% for INSTI DRMs and varied by geographic region. Using the 2% detection threshold, individual DRMs with the highest prevalence were: PI M46IL (5.5%), RT K103NS (3.5%), RT G190ASE (3.1%), T215ISCDVEN (2.5%), RT M41L (2.2%), RT K219QENR (1.7%) and PI D30N (1.6%). INSTI DRMs were detected almost exclusively below the 20% detection threshold, most commonly Y143H (0.4%), Q148R (0.4%), and T66I (0.4%). Conclusions: Use of NGS in this study population resulted in the detection of a large proportion of low-level variants which would not have been detected by traditional Sanger sequencing. Global surveillance studies utilizing NGS should provide a more

[1]  T. F. Rinke de Wit,et al.  Low-abundance drug-resistant HIV-1 variants in antiretroviral drug-naïve individuals: A systematic review of detection methods, prevalence, and clinical impact. , 2019, The Journal of infectious diseases.

[2]  R. Shafer,et al.  2019 update of the drug resistance mutations in HIV-1. , 2019, Topics in antiviral medicine.

[3]  R. Shafer,et al.  Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  V. Calvez,et al.  Impact of next generation sequencing defined HIV pre-treatment drug resistance on virological outcomes in the ANRS 12249 treatment as prevention trial , 2018 .

[5]  Orna Mor,et al.  Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000–2014 , 2017, Journal of the International AIDS Society.

[6]  Michael Huber,et al.  MinVar: A rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing. , 2017, Journal of virological methods.

[7]  Ross J. Harris,et al.  Enhanced surveillance of HIV-1 drug resistance in recently infected MSM in the UK , 2017, The Journal of antimicrobial chemotherapy.

[8]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[9]  J. Lundgren,et al.  Global HIV‐1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial , 2015, HIV medicine.

[10]  Richard J Orton,et al.  Distinguishing low frequency mutations from RT-PCR and sequence errors in viral deep sequencing data , 2015, BMC Genomics.

[11]  Karin J. Metzner,et al.  Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing , 2014, The Journal of antimicrobial chemotherapy.

[12]  Jeroen Aerssens,et al.  VirVarSeq: a low-frequency virus variant detection pipeline for Illumina sequencing using adaptive base-calling accuracy filtering , 2015, Bioinform..

[13]  M. Kozal,et al.  Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve Subjects , 2014, Viruses.

[14]  Anne-Mieke Vandamme,et al.  Automated subtyping of HIV-1 genetic sequences for clinical and surveillance , 2013 .

[15]  K. Metzner,et al.  Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. , 2013, The Journal of infectious diseases.

[16]  D. Webster,et al.  Persistence of HIV-1 Transmitted Drug Resistance Mutations , 2013, The Journal of infectious diseases.

[17]  Ann M. Dennis,et al.  Prevalence of Transmitted Antiretroviral Drug Resistance Differs Between Acutely and Chronically HIV-Infected Patients , 2012, Journal of acquired immune deficiency syndromes.

[18]  Astrid Gall,et al.  Universal Amplification, Next-Generation Sequencing, and Assembly of HIV-1 Genomes , 2012, Journal of Clinical Microbiology.

[19]  C. Boucher,et al.  Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. , 2012, AIDS reviews.

[20]  David L. Robertson,et al.  Analysis of high-depth sequence data for studying viral diversity: a comparison of next generation sequencing platforms using Segminator II , 2012, BMC Bioinformatics.

[21]  M. Wainberg,et al.  Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. , 2011, The Journal of antimicrobial chemotherapy.

[22]  K. Metzner,et al.  Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure , 2011 .

[23]  W. Heneine,et al.  Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.–2006 , 2010, AIDS.

[24]  A. Wensing,et al.  Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. , 2010, Antiviral research.

[25]  Anne-Mieke Vandamme,et al.  Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update , 2009, PloS one.

[26]  Gregory S Turenchalk,et al.  Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. , 2009, The Journal of infectious diseases.

[27]  Michael Monsour,et al.  Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.

[28]  D. Richman,et al.  Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus Infection , 2008, Journal of Virology.

[29]  M. Kozal,et al.  Natural Polymorphism of the HIV-1 Integrase Gene and Mutations associated with Integrase Inhibitor Resistance , 2007, Antiviral therapy.

[30]  Allan E. Rodriguez,et al.  Prevalence of Antiretroviral Drug Resistance and Resistance-Associated Mutations in Antiretroviral Therapy-Naïve HIV-Infected Individuals from 40 United States Cities , 2007, HIV clinical trials.

[31]  A. Geretti.  Epidemiology of antiretroviral drug resistance in drug-naïve persons , 2007, Current opinion in infectious diseases.

[32]  W. Heneine,et al.  The Fitness Cost of Mutations Associated with Human Immunodeficiency Virus Type 1 Drug Resistance Is Modulated by Mutational Interactions , 2006, Journal of Virology.

[33]  Tommy F. Liu,et al.  Web resources for HIV type 1 genotypic-resistance test interpretation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  D. Pillay,et al.  The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy , 2006, AIDS.

[35]  M. Kozal,et al.  Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.